BioAgilytix
BioAgilytix is recorded as a service provider in 323 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 323 trials · Latest update first
An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
Sponsor DICE Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study used 46 sites across Canada (10), Czechia (3), Germany (2), Hungary (3), Poland (8), Spain (3), the United Kingdom (3), and the United States (14).
- A total of 293 participants signed consent and 229 were randomized, compared with approximately 225 participants planned for randomization.
- Enrollment was geographically balanced between North America/Western Europe (53.1%) and Eastern Europe (46.9%).
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour
Sponsor Synox Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-blind, Placebo‑controlled, Dose‑ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
Sponsor Blueprint Medicines Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
Sponsor BioNTech SE
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
Sponsor 4d Molecular Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
Sponsor Corvus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Sponsor Spyre Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 Years of Age) with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
Sponsor BioNTech SE
- Start (EU)
- Latest update
- Estimated end
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for BioAgilytix?
The 2026-10-09 snapshot links BioAgilytix to 323 distinct CTIS trials. Recorded services include Laboratory services, Immunogenicity assessments, Analysis of cellular IG, Lab- Anti-CAR antibody testing, among 116 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for BioAgilytix?
The most frequently recorded therapeutic areas are Immunology, Solid Tumor Oncology, Neurology, Genetic and Congenital Disorders. Recorded phases include Phase 2, Phase 3, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to BioAgilytix conducted?
The linked trials record locations in 27 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where BioAgilytix delivered services.
What can this page tell me about BioAgilytix's trial experience?
Browse 323 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 9 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under BioAgilytix. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- BioAgilytix Europe GmbH
- Bioagilytix Labs LLC
- Bioagilytix Labs, LLC